Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT-Reference-Cited by-同舟云学术

Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT

Published:2021-12-01 Issue:2 Volume:57 Page:261-270
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Czerw Tomasz^ORCID,Iacobelli Simona,Malpassuti Vittoria,Koster Linda,Kröger Nicolaus^ORCID,Robin Marie^ORCID,Maertens Johan,Chevallier Patrice,Watz Emma,Poiré Xavier^ORCID,Snowden John A.,Kuball Jürgen^ORCID,Kinsella Francesca^ORCID,Blaise Didier^ORCID,Reményi Péter,Mear Jean-Baptiste,Cammenga Jörg,Rubio Marie Thérèse,Maury Sebastien,Daguindau Etienne,Finnegan Damian,Hayden Patrick^ORCID,Hernández-Boluda Juan Carlos^ORCID,McLornan Donal^ORCID,Yakoub-Agha Ibrahim^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-021-01540-2.pdf

Reference36 articles.

1. Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92:289–97.

2. Schieber M, Crispino JD, Stein B. Myelofibrosis in 2019: moving beyond JAK2 inhibition. Blood Cancer J. 2019;9:74.

3. Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30:1701–7.

4. Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10:55.

5. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 2018;32:1057–69.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group;The Lancet Haematology;2024-01

2. The management of myelofibrosis: A British Society for Haematology Guideline;British Journal of Haematology;2023-12

3. How I treat transplant-eligible patients with myelofibrosis;Blood;2023-11-16

4. Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP);Bone Marrow Transplantation;2023-09-06

5. Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes;Frontiers in Oncology;2023-08-10